Influence of RANKL inhibition on immune system in the treatment of bone diseases

Joint Bone Spine

Volumn 75, Issue 1, 2008, Pages 5-10

  Fouque Aubert, Anne ^a   Chapurlat, Roland ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

B cell; Dendritic cell; OPG; Osteoclast; RANK; RANKL; T cell

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

BONE DISEASE; BONE METABOLISM; CELL ACTIVATION; CELL DIFFERENTIATION; HELPER CELL; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; MONOCYTE; NONHUMAN; OSTEOCLAST; OSTEOPOROSIS; SHORT SURVEY;

ANIMALS; ANTIBODIES, MONOCLONAL; ARTHRITIS; BONE DISEASES; BONE REMODELING; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; HUMANS; LYMPH NODES; MONOCYTES; RANK LIGAND; T-LYMPHOCYTES;

EID: 37649000905     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2007.05.004     Document Type: Short Survey

References (42)

1. Yasuda H., Shima N., Nakagawa N., Yamaguchi K., Kinosaki M., Goto M., et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone 25 (1999) 109-113
2. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
3. Ikeda T., Kasai M., Utsuyama M., and Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. Endocrinology 142 (2001) 1419-1426
4. Kim N., Odgren P.R., Kim D.K., Marks Jr. S.C., and Choi Y. Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene. Proc Natl Acad Sci U S A 97 (2000) 10905-10910
5. Jimi E., Akiyama S., Tsurukai T., Okahashi N., Kobayashi K., Udagawa N., et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol 163 (1999) 434-442
6. Jones D.H., Kong Y.Y., and Penninger J.M. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 61 Suppl. 2 (2002) ii32-ii39
7. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendriticcell function. Nature 390 (1997) 175-179
8. Nakagawa N., Kinosaki M., Yamaguchi K., Shima N., Yasuda H., Yano K., et al. RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis. Biochem Biophys Res Commun 253 (1998) 395-400
9. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96 (1999) 3540-3545
10. Yoshida H., Hayashi S., Kunisada T., Ogawa M., Nishikawa S., Okamura H., et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345 (1990) 442-444
11. Tanaka S., Takahashi N., Udagawa N., Tamura T., Akatsu T., Stanley E.R., et al. Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest 91 (1993) 257-263
12. Tsurukai T., Takahashi N., Jimi E., Nakamura I., Udagawa N., Nogimori K., et al. Isolation and characterization of osteoclast precursors that differentiate into osteoclasts on calvarial cells within a short period of time. J Cell Physiol 177 (1998) 26-35
13. Kim H.H., Lee D.E., Shin J.N., Lee Y.S., Jeon Y.M., Chung C.H., et al. Receptor activator of NF-kappaB recruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett 443 (1999) 297-302
14. Walsh M.C., and Choi Y. Biology of the TRANCE axis. Cytokine Growth Factor Rev 14 (2003) 251-263
15. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
16. Tan K.B., Harrop J., Reddy M., Young P., Terrett J., Emery J., et al. Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells. Gene 204 (1997) 35-46
17. Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T., et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234 (1997) 137-142
18. Mizuno A., Murakami A., Nakagawa N., Yasuda H., Tsuda E., Morinaga T., et al. Structure of the mouse osteoclastogenesis inhibitory factor (OCIF) gene and its expression in embryogenesis. Gene 215 (1998) 339-343
19. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
20. Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Riggs B.L., and Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250 (1998) 776-781
21. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Spelsberg T.C., and Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 (1999) 4367-4370
22. Li P., Schwarz E.M., O'Keefe R.J., Ma L., Boyce B.F., and Xing L. RANK signaling is not required for TNFalpha-mediated increase in CD11(hi) osteoclast precursors but is essential for mature osteoclast formation in TNFalpha-mediated inflammatory arthritis. J Bone Miner Res 19 (2004) 207-213
23. Seshasayee D., Wang H., Lee W.P., Gribling P., Ross J., Van Bruggen N., et al. A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response. J Biol Chem 279 (2004) 30202-30209
24. Wong B.R., Josien R., Lee S.Y., Sauter B., Li H.L., Steinman R.M., et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186 (1997) 2075-2080
25. Bachmann M.F., Wong B.R., Josien R., Steinman R.M., Oxenius A., and Choi Y. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 189 (1999) 1025-1031
26. Josien R., Li H.L., Ingulli E., Sarma S., Wong B.R., Vologodskaia M., et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 191 (2000) 495-502
27. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
28. Yun T.J., Tallquist M.D., Aicher A., Rafferty K.L., Marshall A.J., Moon J.J., et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 166 (2001) 1482-1491
29. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 13 (1999) 2412-2424
30. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
31. Pettit A.R., Ji H., von Stechow D., Muller R., Goldring S.R., Choi Y., et al. TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol 159 (2001) 1689-1699
32. Redlich K., Hayer S., Maier A., Dunstan C.R., Tohidast-Akrad M., Lang S., et al. Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum 46 (2002) 785-792
33. Saidenberg-Kermanac'h N., Corrado A., Lemeiter D., deVernejoul M.C., Boissier M.C., and Cohen-Solal M.E. TNF-alpha antibodies and osteoprotegerin decrease systemic bone loss associated with inflammation through distinct mechanisms in collagen-induced arthritis. Bone 35 (2004) 1200-1207
34. Song K., Chen Y., Goke R., Wilmen A., Seidel C., Goke A., et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J Exp Med 191 (2000) 1095-1104
35. Wang J., Zheng L., Lobito A., Chan F.K., Dale J., Sneller M., et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell 98 (1999) 47-58
36. Leverkus M., Walczak H., McLellan A., Fries H.W., Terbeck G., Brocker E.B., et al. Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis. Blood 96 (2000) 2628-2631
37. Stolina M., Guo J., Faggioni R., Brown H., and Senaldi G. Regulatory effects of osteoprotegerin on cellular and humoral immune responses. Clin Immunol 109 (2003) 347-354
38. Bekker P.J., Holloway D., Nakanishi A., Arrighi M., Leese P.T., and Dunstan C.R. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16 (2001) 348-360
39. Body J.J., Greipp P., Coleman R.E., Facon T., Geurs F., Fermand J.P., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (2003) 887-892
40. Bekker P.J., Holloway D.L., Rasmussen A.S., Murphy R., Martin S.W., Leese P.T., et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2005 20 (2004) 2275-2282
41. McClung M.R., Lewiecki E.M., Cohen S.B., Bolognese M.A., Woodson G.C., Moffett A.H., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354 (2006) 821-831
42. Roux S. RANKL inhibitors: a bright future?. Joint Bone Spine 76 (2006) 129-131